Delcath Systems Publishes Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

MT Newswires Live

05/27

Delcath Systems (DCTH) said late Tuesday it published two investigator-initiated trials-in-progress abstracts on May 21.

The company said these abstracts will be presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago, highlighting ongoing clinical investigations of Delcath's percutaneous hepatic perfusion with melphalan using the HEPZATO KIT (TM) Hepatic Delivery System in metastatic melanoma involving the liver.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2638523168"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638523168\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638523168?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638523168","market":"us","top_or_hot":-1,"title":"Delcath Systems Publishes Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> (DCTH) said late Tuesday it published two investigator-initiated trials-in-progress abstracts on May 21.</p><p>The company said these abstracts will be presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago, highlighting ongoing clinical investigations of Delcath's percutaneous hepatic perfusion with melphalan using the HEPZATO KIT (TM) Hepatic Delivery System in metastatic melanoma involving the liver.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Delcath Systems Publishes Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDelcath Systems Publishes Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-27 05:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/DCTH\">Delcath Systems</a> (DCTH) said late Tuesday it published two investigator-initiated trials-in-progress abstracts on May 21.</p><p>The company said these abstracts will be presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago, highlighting ongoing clinical investigations of Delcath's percutaneous hepatic perfusion with melphalan using the HEPZATO KIT (TM) Hepatic Delivery System in metastatic melanoma involving the liver.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGS","symbol_name":"Progress Software Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638523168","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638523168","pubTimestamp":1779830621,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Delcath Systems  said late Tuesday it published two investigator-initiated trials-in-progress abstracts on May 21.The company said these abstracts will be presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago, highlighting ongoing clinical investigations of Delcath's percutaneous hepatic perfusion with melphalan using the HEPZATO KIT  Hepatic Delivery System in metastatic melanoma involving the liver.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRGS":"Progress Software Corporation","BK4099":"汽车制造商","03160":"华夏日股对冲","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4555":"新能源车","TM":"丰田汽车","BK4097":"系统软件","BK4082":"医疗保健设备","BK4604":"机器人概念","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","DCTH":"迪卡斯"},"translate_title":"Delcath Systems发布了两份ASCO 2026研究者发起的正在进行的试验摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCTH":1,"PRGS":1.5,"TM":1,"03160":0.6},"content_text":"Delcath Systems (DCTH) said late Tuesday it published two investigator-initiated trials-in-progress abstracts on May 21.The company said these abstracts will be presented at the 2026 American Society of Clinical Oncology annual meeting in Chicago, highlighting ongoing clinical investigations of Delcath's percutaneous hepatic perfusion with melphalan using the HEPZATO KIT (TM) Hepatic Delivery System in metastatic melanoma involving the liver.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}